McIntyre Partnerships Sold Its Position in ICON Public Limited Company (ICLR). Here’s Why

Mc Intyre Partnerships Sold Its Position in ICON Public Limited Company (ICLR). Here’s Why Soumya Eswaran Mon, June 1, 2026 at 11:36 PM GMT+7 3 min read ICLR ^RUT MSTR US-based investment company, Mc Intyre Partnerships, returned -19% gross and -20% net in the first quarter of 2026 compared to the Russell 2000 Value Index’s 5% return. A copy of the letter can be downloaded here. Since inception, the fund has returned ~14% gross and ~10% net per annum, surpassing the benchmark’s return of ~7% per annum. The Q1 results were disappointing for the fund, primarily due to a significant decline in the shares of life science tools and medical device stocks, in which the fund has substantial investments, as well as specific issues related to QDEL, a company in the life science tools sector. By the end of the month, the fund s exposure was recorded at 123% long, 27% short, and 97% net. In addition, you can check the Strategy’s top 5 holdings to determine its best picks for 2026.

In its first-quarter 2026 investor letter, McIntyre Partnerships highlighted stocks like ICON Public Limited Company (NASDAQ:ICLR). ICON Public Limited Company (NASDAQ:ICLR) is a clinical research organization that provides outsourced development and commercialization services to the pharmaceutical, biotechnology, and medical device industries. On May 29, 2026, ICON Public Limited Company (NASDAQ:ICLR) stock closed at $136.07 per share. One-month return of ICON Public Limited Company (NASDAQ:ICLR) was 20.42%, and its shares gained 4.60% over the past 52 weeks. ICON Public Limited Company (NASDAQ:ICLR) has a market capitalization of about $10.31 billion.

McIntyre Partnerships stated the following regarding ICON Public Limited Company (NASDAQ:ICLR) in its Q1 2026 investor letter: